The estimated Net Worth of Athena Countouriotis is at least $4.88 Million dollars as of 9 February 2022. Dr Countouriotis owns over 2,971 units of Turning Point Therapeutics Inc stock worth over $3,643,159 and over the last 10 years he sold TPTX stock worth over $107,847. In addition, he makes $1,130,800 as Pres und CEO & Director at Turning Point Therapeutics Inc.
Dr has made over 12 trades of the Turning Point Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 2,971 units of TPTX stock worth $107,847 on 9 February 2022.
The largest trade he's ever made was exercising 60,000 units of Turning Point Therapeutics Inc stock on 9 February 2021 worth over $192,000. On average, Dr trades about 4,092 units every 59 days since 2015. As of 9 February 2022 he still owns at least 47,930 units of Turning Point Therapeutics Inc stock.
You can see the complete history of Dr Countouriotis stock trades at the bottom of the page.
Dr. Athena Maria Countouriotis M.D. is the Pres, CEO & Director at Turning Point Therapeutics Inc.
As the Pres und CEO & Director of Turning Point Therapeutics Inc, the total compensation of Dr D at Turning Point Therapeutics Inc is $1,130,800. There are 3 executives at Turning Point Therapeutics Inc getting paid more, with Yi Larson having the highest compensation of $12,579,400.
Dr D is 49, he's been the Pres und CEO & Director of Turning Point Therapeutics Inc since . There are 13 older and 5 younger executives at Turning Point Therapeutics Inc. The oldest executive at Turning Point Therapeutics Inc is Garry Nicholson, 65, who is the Independent Director.
Over the last 6 years, insiders at Turning Point Therapeutics Inc have traded over $45,947,838 worth of Turning Point Therapeutics Inc stock and bought 2,385,408 units worth $60,168,920 . The most active insiders traders include Plc Gsk, Patrick Machado und Advisors Llc Orbi Med Capit.... On average, Turning Point Therapeutics Inc executives and independent directors trade stock every 21 days with the average trade being worth of $4,727,594. The most recent stock trade was executed by Paolo Tombesi on 27 July 2022, trading 1,183 units of TPTX stock currently worth $88,654.
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company's lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients. The company's pipeline of drug candidates also includes TPX-0022, targeting MET, CSF1R and SRC, which is being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in RET; and TPX-0131, a next-generation ALK inhibitor currently pending IND submission. Turning Point's next-generation kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
Turning Point Therapeutics Inc executives and other stock owners filed with the SEC include: